Galliprant (Grapiprant) Side Effects in Dogs

Galliprant (active ingredient: grapiprant) is an FDA-approved prescription NSAID manufactured by Elanco, used to control pain and inflammation from osteoarthritis in dogs. Unlike traditional NSAIDs that broadly inhibit COX enzymes, grapiprant is a first-of-its-kind piprant-class drug that selectively blocks the EP4 prostaglandin receptor — the primary receptor driving OA pain. This targeted mechanism is designed to spare many of the gastrointestinal, kidney, and liver pathways disrupted by older NSAIDs. However, Galliprant still has real side effects that every dog owner needs to understand. In November 2024, the FDA worked with Elanco to update the Galliprant label with additional safety warnings based on post-approval adverse drug experience reports. Here are the 10 most important facts about Galliprant side effects.

• 1
  What are the most common side effects of Galliprant in dogs? Most common (from FDA field study, 285 dogs): Vomiting (17% Galliprant vs. 6% placebo) · Diarrhea/soft stool (12% vs. 9%) · Decreased appetite/anorexia (6% vs. 5%) · Lethargy (4% vs. 1%) · Rare: buccal (mouth) ulcer · Rare: immune-mediated hemolytic anemia (1 case)

  The FDA-approved label for Galliprant (published on DailyMed NIH, updated 2024) reports adverse reactions from a controlled 28-day field study of 285 dogs. In that study, vomiting was reported in 24 of 141 Galliprant-treated dogs (17%) compared to 9 of 144 control dogs (6%). Diarrhea or soft stool occurred in 17 Galliprant-treated dogs (12%) versus 13 controls (9%). Decreased appetite or inappetence affected 9 Galliprant dogs (6%) versus 7 controls (5%). Lethargy was reported in 6 Galliprant-treated dogs (4%) versus 2 controls (1%). One Galliprant-treated dog developed a buccal (mouth) ulcer, and one developed immune-mediated hemolytic anemia. These are the reactions with established frequency from clinical trial data. Additional adverse events have been reported through the FDA’s post-approval adverse drug experience reporting system — these are listed separately because causal relationships cannot always be confirmed from reporting data alone (see Takeaway #3). The FDA updated the Galliprant label in late 2024 to strengthen safety warnings based on accumulated post-approval data.
• 2
  Will Galliprant side effects go away on their own? Mild GI side effects (vomiting, loose stool) often resolve within a few days, especially with food · Persistent or worsening GI symptoms, any blood in vomit or stool, or any neurological symptoms should be reported to your vet immediately · Do not continue Galliprant through serious side effects hoping they will resolve — contact your vet first

  Whether Galliprant side effects go away depends entirely on the type and severity of the reaction. Mild gastrointestinal upset — loose stools, occasional vomiting — is the most commonly reported issue and often improves on its own within a few days as your dog adjusts to the medication. The Ask A Vet 2025 guide notes that giving Galliprant with a small amount of food (such as a few pieces of boiled chicken or a soft treat) can reduce GI distress in dogs who experience stomach upset on an empty stomach, even though fasted dosing maximizes absorption. However, not all side effects are transient. Persistent vomiting (more than 1–2 episodes), ongoing diarrhea, any blood in vomit or stool (black/tarry stools indicate GI bleeding), significant lethargy, or any neurological symptom — stumbling, confusion, seizures — are not expected to resolve on their own and require immediate veterinary evaluation. The general guidance from the FDA label and veterinary sources: if you are unsure whether what you are seeing is a normal adjustment reaction or something more serious, contact your veterinarian rather than waiting.
• 3
  What are the rare but serious side effects of Galliprant? From FDA/DailyMed post-approval experience data: GI ulcer · Pancreatitis (elevated pancreatic enzymes) · Melena (black, tarry, digested blood in stool) · GI bleeding · Elevated liver enzymes · Increased BUN/creatinine (kidney markers) · Renal failure · Urinary incontinence · Polyuria/polydipsia (excessive drinking/urinating) · Ataxia (stumbling, loss of coordination) · Seizures · Anemia · Thrombocytopenia (low platelets) · Weight loss

  Beyond the common GI side effects seen in the clinical trial, Galliprant’s post-approval adverse drug experience reports — collected by Elanco and submitted to the FDA’s Center for Veterinary Medicine — document a broader range of serious events. Per the Drugs.com and DailyMed NIH label (2024 post-approval data): gastrointestinal events include GI ulcer, pancreatitis, melena (black stools indicating digested blood), bloody stool, hypoalbuminemia (low blood protein), abdominal pain, and GI ulcer. Liver-related events include elevated liver enzymes. Kidney and urinary events include increased BUN or creatinine (kidney function markers), polydipsia, urinary incontinence, polyuria, and renal failure. Neurological events include ataxia and seizures. Hematologic events include anemia and thrombocytopenia. General events include anorexia, lethargy, weight loss, panting, and hyperactivity. The FDA is explicit that not all adverse events are reported to the FDA/CVM, and that causal relationships cannot always be established from post-marketing surveillance data. These are rare events, not expected outcomes — but they are real enough that the FDA and AAHA (March 2025) identified them as warranting updated label warnings.
• 4
  Can Galliprant cause neurological side effects in dogs? Rare — neurological side effects are NOT among the most common Galliprant reactions · Post-approval adverse event reports include: ataxia (stumbling, incoordination) and seizures · These are rare, with GI effects far more commonly reported · Dogs with pre-existing neurological conditions or kidney/liver disease may have higher risk · MDR1-mutation dogs (collies, shelties, Australian shepherds) have 4–6x higher drug exposure and may be more susceptible

  Neurological side effects from Galliprant are documented in the FDA post-approval adverse drug experience data (DailyMed NIH, 2024) — specifically ataxia (loss of coordination, stumbling, weakness) and seizures. These are categorized in the neurologic section of post-approval adverse event data, which means they have been reported in real-world use but are not among the most commonly observed reactions. The Bestie Paws Hospital review (March 2025) notes that neurological symptoms are rare, with most side effects relating to the GI system. In some cases, neurological symptoms may reflect an underlying condition that was previously undetected rather than a direct effect of the drug — dogs with pre-existing neurological disorders, liver disease, or kidney dysfunction may be more susceptible because altered organ function can affect how drugs are metabolized in the body. A particular concern involves dogs with the MDR1 gene mutation (homozygous), which is common in collies, Shelties, and Australian Shepherds. Research published in the Journal of Veterinary Pharmacology and Therapeutics (Heit et al., 2021, PMC/NIH) found that MDR1-deficient collies had approximately 4-fold higher peak blood concentrations and 6-fold greater total drug exposure (AUC) compared to normal Beagles at the same labeled dose — significantly increasing the risk of side effects in these breeds. If your dog is stumbling, disoriented, having balance problems, or experiences a seizure while on Galliprant, stop the medication and contact your veterinarian immediately.
• 5
  Can Galliprant cause kidney failure in dogs? Kidney failure is listed in the post-approval adverse event data as a rare event · Traditional NSAIDs are more commonly associated with kidney damage than Galliprant, because Galliprant spares the COX pathway · However, increased BUN and creatinine (kidney stress markers) have been reported in post-marketing surveillance · Dogs with pre-existing kidney disease require extra caution and frequent monitoring · Baseline and periodic bloodwork is recommended for long-term use

  Renal failure appears in Galliprant’s post-approval adverse event data (DailyMed NIH, 2024), along with increased blood urea nitrogen (BUN) and creatinine — laboratory markers of kidney stress or injury. This is important context: while Galliprant’s EP4-receptor mechanism theoretically has a more favorable kidney profile than traditional NSAIDs that block the COX pathway (which is important for maintaining renal blood flow), the kidney is not entirely free from EP4 receptor activity. The FDA label notes that the EP4 receptor is involved in the kidneys’ antinatiuretic effect, which means grapiprant’s blockade of this receptor can potentially affect kidney function. The AAHA drug label update report (March 2025) specifically highlighted that the updated Galliprant label now instructs veterinarians to use caution with concurrent administration of Galliprant and nephrotoxic drugs. The Ask A Vet 2025 guide notes that some dogs with mild kidney issues may tolerate Galliprant better than traditional NSAIDs, but this must be evaluated on an individual basis by a veterinarian. Kidney failure as a Galliprant-specific outcome is a rare post-marketing report — it is not an expected routine outcome of therapy — but dogs with any degree of kidney disease should only take Galliprant under close veterinary supervision with periodic bloodwork monitoring.
• 6
  How long do Galliprant side effects last? Grapiprant has a half-life of approximately 4–5 hours in dogs · Most drug-related GI side effects resolve within 1–3 days of stopping the medication · More serious effects (elevated liver or kidney enzymes) may take longer to normalize and require veterinary management · If side effects are severe or persist beyond 24–48 hours after stopping the drug, contact your vet · Do not restart Galliprant after a significant adverse event without veterinary clearance

  The pharmacokinetics of grapiprant help predict how long side effects might persist after the drug is stopped. Research published in the Journal of Veterinary Pharmacology and Therapeutics (Heit et al., 2021, PMC/NIH) found a median terminal half-life of approximately 4.3 hours after the first dose in MDR1-deficient collies, with peak blood concentrations reached within 1 hour of dosing. In normal dogs (Beagle pharmacokinetic data), the half-life is similarly short — typically 4–5 hours. This means the drug clears relatively quickly from a dog’s system: most of the grapiprant should be metabolically cleared within 24 hours of stopping the last dose. Mild GI side effects — occasional vomiting, loose stools — that are directly related to the drug’s presence in the system typically resolve within 1–3 days of discontinuation. However, if the drug has caused more significant effects — such as GI ulceration, elevated liver enzymes, or kidney injury — those underlying tissue changes can persist and may require active veterinary treatment (fluids, protective medications, dietary support) beyond the point when the drug itself has cleared. A single missed dose or brief course interruption for mild vomiting is unlikely to cause lasting issues; persistent, severe, or organ-specific side effects require veterinary management.
• 7
  Is it better to give Galliprant in the morning or at night? No official guidance specifies morning vs. night — the key requirement is consistency (same time every 24 hours) · Give on an empty stomach for maximum absorption (at least 1 hour before food) · If GI upset occurs on an empty stomach, giving with a small amount of food is an acceptable compromise · Most owners prefer morning dosing for convenient monitoring during the day · Consult your veterinarian for the timing that best suits your dog’s routine and tolerance

  The FDA-approved label for Galliprant (DailyMed NIH) specifies dosing at 2 mg/kg (0.9 mg/lb) once every 24 hours, but does not mandate a specific time of day. The critical clinical detail about timing relates to food: Galliprant is best absorbed when given on an empty stomach — the fasted state produces higher peak blood concentrations than feeding before dosing. The Elanco product information and pharmacokinetic data confirm that feeding reduces drug absorption. For this reason, the label recommends giving Galliprant at least one hour before feeding. In practice, morning dosing before breakfast is the most common approach — it aligns naturally with dogs’ feeding routines and allows owners to monitor their dog during the waking hours after dosing, when any GI reactions (vomiting, loose stool) are most likely to appear. The Ask A Vet 2025 vet guide and Bestie Paws (July 2025) both note that if a dog experiences significant GI upset when dosed on an empty stomach, giving it with a small low-fat snack (such as boiled chicken or a soft treat) is a clinically acceptable compromise — tolerability takes priority over maximizing absorption. Whatever time you choose, consistency matters: give Galliprant at the same time each day to maintain steady therapeutic levels.
• 8
  What is the correct Galliprant dosage for dogs? FDA-approved dose: 2 mg/kg (0.9 mg/lb) orally once daily · Tablets: 20 mg, 60 mg, 100 mg · Only 20 mg and 60 mg tablets are scored (can be split) — do NOT split 100 mg tablets · Minimum: dogs must weigh at least 8 lbs (3.6 kg) and be at least 9 months old · Dose range in practice: 1.5–2.9 mg/kg depending on body weight band and tablet size · Use the lowest effective dose for the shortest duration needed

  The FDA-approved label (DailyMed NIH, NADA #141-455) establishes the dose of Galliprant at 2 mg/kg (0.9 mg/lb) once daily by mouth. Galliprant is available in three tablet strengths — 20 mg, 60 mg, and 100 mg. Only the 20 mg and 60 mg tablets are scored, meaning they can be safely split in half to achieve the nearest half-tablet increment; the 100 mg tablet should not be split. Because of the commercially available tablet sizes, the effective dose a dog receives in clinical practice typically ranges from 1.5 to 2.9 mg/kg — this range is within the therapeutic window per the label, so precision to an exact 2 mg/kg is not always achievable or required. The drug is not approved for dogs weighing under 8 lbs (3.6 kg) or younger than 9 months of age, because safety data is not available for these patients. Galliprant has not been studied in breeding dogs or pregnant or nursing females. The label principle from the FDA is clear: use the lowest effective dose for the shortest duration consistent with individual patient response. This is especially important for long-term OA management, where dose reduction can be considered if adequate pain control is achieved.
• 9
  Galliprant vs. carprofen — which is safer and more effective? Neither is categorically superior for all dogs · Carprofen: faster-acting, more established (25+ years; ~30 million dogs), more affordable, broader GI/kidney risk profile · Galliprant: more targeted EP4 mechanism, potentially fewer GI side effects for some dogs especially seniors, more expensive, newer drug · Studies: grapiprant equivalent to carprofen for post-surgical pain (AJVR 2022); carprofen was more effective than grapiprant in an acute experimental synovitis model (PubMed, Budsberg 2019) · Best choice: determined by your individual dog’s health profile — your vet decides

  The Galliprant vs. carprofen comparison is one of the most searched questions among dog owners managing OA pain. Both are FDA-approved prescription NSAIDs for dogs, but they work differently. Carprofen inhibits both COX-1 and COX-2 enzymes throughout the body — it has over 25 years of clinical use history and has been prescribed to approximately 30 million dogs. Galliprant (grapiprant) is a newer piprant-class drug that specifically blocks the EP4 receptor. Peer-reviewed research provides a nuanced picture: a study in the American Journal of Veterinary Research (2022) comparing grapiprant and carprofen for post-surgical pain in Beagles found the two drugs were equivalent in managing inflammatory pain after ovariohysterectomy. A randomized double-blind clinical trial published in the Journal of Veterinary Internal Medicine (Cassemiche et al., 2024, PMC/NIH) found grapiprant and meloxicam were similarly effective for postoperative joint pain management. However, a separate PubMed study (Budsberg et al., 2019) testing both drugs in an acute experimental synovitis model found carprofen was the most effective treatment — and grapiprant the least effective. For long-term OA management, Galliprant’s selective EP4 mechanism is generally considered to have a more favorable GI and kidney safety profile than traditional NSAIDs for certain dogs — particularly seniors or dogs with previous GI sensitivity. Carprofen remains more affordable and has a more extensive long-term track record. The right choice is not universal — it depends on your dog’s age, weight, kidney/liver health, GI history, and other medications.
• 10
  How long can a dog stay on Galliprant? Indefinitely if tolerated and monitored — but only under veterinary supervision with periodic bloodwork · The clinical trial documented safety over 28 days; real-world use shows many dogs thrive on it for months to years · Require: baseline bloodwork (complete blood count + blood chemistry panel) before starting · Periodic bloodwork while on long-term therapy (frequency set by your vet) · The label principle: lowest effective dose for shortest duration consistent with individual patient response

  Galliprant is approved for the management of osteoarthritis — a chronic, lifelong condition — meaning long-term use is the expected clinical reality for many dogs. The FDA controlled field study documented safety over 28 days, but the Bestie Paws dosing guide (July 2025) and veterinary clinical experience show that many dogs tolerate Galliprant for months or even years when appropriately monitored. The key qualifier is monitoring. The updated Galliprant label (AAHA, March 2025; DailyMed NIH 2024) now explicitly states that a thorough history, physical examination, and laboratory testing should be performed prior to administration, and that caution is required with concurrent administration of nephrotoxic or protein-bound drugs. In practice, your veterinarian will typically recommend a complete blood count and blood chemistry panel (which evaluates liver and kidney function) before starting Galliprant, and at periodic intervals during long-term therapy — typically every 6–12 months for stable patients, more frequently for dogs with pre-existing organ disease or other risk factors. The label instruction to use the lowest effective dose for the shortest duration is not a directive to stop the drug arbitrarily — it is a principle of responsible prescribing that means the dose should be reassessed periodically to confirm it is still necessary and appropriate for your dog’s current level of pain.

Sources: FDA/DailyMed NIH (GALLIPRANT label NADA #141-455; field study 285 dogs; post-approval ADE data 2024; dailymed.nlm.nih.gov); AAHA Trends Magazine (FDA label safety updates including Galliprant; Mar 2025; updated safety warnings + pre-treatment lab testing); GoodRx (Galliprant dogs; Aug 2025; MDR1 collies; dosing); PetMD (Galliprant dogs; Jul 2024; Oct 2025; overdose signs); Drugs.com (Galliprant post-approval ADE complete list; Mar 2026); Elanco/yourpetandyou.elanco.com (Galliprant official product info; EP4 mechanism); Ask A Vet Dr. Duncan Houston BVSc (2025 vet guide grapiprant; fasted dosing; GI tolerance); Bestie Paws Hospital (side effects Dec 2025; neurological Mar 2025; dosing Jul 2025); PMC/NIH Heit et al 2021 JVPT (MDR1 collies PK; 4x Cmax 6x AUC vs beagles; t½ 4.3h); PMC/NIH Sartini et al 2021 JVPT (grapiprant snapshot; current knowledge); PMC/NIH Cassemiche et al 2024 JVIM (grapiprant vs meloxicam RCT postop joint pain; equivalent); AJVR 2022 (grapiprant vs carprofen OVH beagles; equivalent inflammatory pain); PubMed Budsberg et al 2019 (carprofen more effective grapiprant in acute synovitis model); A-Z Animals (dosing chart Aug 2024); ASPCA (1-888-426-4435)

Sources: FDA/DailyMed NIH (label NADA #141-455; 2024); AAHA Trends Magazine (label update Mar 2025); PMC/NIH Heit et al 2021 JVPT (MDR1 PK data); GoodRx (Aug 2025; washout period); Drugs.com (full post-approval ADE list)

The following is a general reference dosage chart based on the FDA-approved label (2 mg/kg once daily, nearest half-tablet increment). Always confirm your dog’s specific dose with your veterinarian — do not adjust or calculate doses at home without veterinary guidance. Only 20 mg and 60 mg tablets are scored (splittable). The 100 mg tablet should not be split.

Sources: FDA/DailyMed NIH (NADA #141-455 label; dosing 0.9 mg/lb; only 20 mg + 60 mg scored); Elanco dosage chart PDF; GoodRx (Aug 2025; MDR1; 5–7 day washout); Ask A Vet Dr. Houston BVSc (2025; fasted vs. fed; GI tolerance adjustments)

Sources: FDA/DailyMed NIH (NADA #141-455 label; BEACH; contraindications; field study albumin; pre-treatment lab testing per 2024–2025 label update); AAHA Trends Magazine (FDA label updates Mar 2025 — pre-treatment labs; caution nephrotoxic + protein-bound drugs; safety warnings); GoodRx (Aug 2025; washout 5–7 days; MDR1; cardiac/breeding contraindications); Drugs.com (full post-approval ADE list; Mar 2026); PMC/NIH Heit et al 2021 JVPT (MDR1 PK; 4x Cmax 6x AUC; vomiting 25% MDR1 collies); Ask A Vet Dr. Houston BVSc 2025 (fasted dosing; tolerability; bloodwork frequency); Bestie Paws Hospital (side effects Dec 2025; neurological Mar 2025; dosing Jul 2025)